Godex for fatty liver: a Phase 3 trial
Part of Digestive system clinical trials.
This study tests an investigational supplement called Godex Carnitine Orotate Complex to see if it helps people with nonalcoholic fatty liver disease (NAFLD) lower their liver enzymes and reduce liver fat. It may be a good option if you have elevated liver enzymes and evidence of fat in your liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 75 years old.
- You have elevated liver enzymes (AST or ALT) on your blood tests—either 60 or more, or 40–59 for at least 3 months.
- Your doctor finds evidence of fat in your liver (at least 7% on an MRI scan).
- If you have diabetes, your blood sugar control is good (HbA1c under 8.5%) and your diabetes medicines haven't changed in the last 12 weeks.
- You are willing to follow study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
This study tests a medicine called carbocisteine to see if it can help treat nonalcoholic fatty liver disease (NAFLD). If you have a fatty liver and no other liver or kidney conditions, this trial may explore whether this drug is safe and effective for you.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.